DMTC is harnessing expertise and deploying resources to play its role in contributing to the national response to the COVID-19 pandemic.
Australia’s response is of vital importance not only for our own citizens but also in likely humanitarian aid assistance to countries in our region.
Building supply chain resilience and pursuing rapid and innovative responses to the challenge posed by the Coronavirus will assist in the short-term response as well as contributing to the longer-term economic recovery effort.
A DMTC National COVID Technology Capability Development Portal has been established to support the coordination of pandemic response capability implementation, through the collation and exchange of end user requirements with available and emerging information and technologies. A strong focus of the initial effort will be through engagement with Australian academic institutions and research and development organisations.
DMTC is now accepting proposals from researchers and the industrial sector that span a broad range of technologies and disciplines, from medical countermeasure developments to industrial innovations and manufacturing solutions. Proposals will be carefully assessed by subject matter experts for their potential to make a difference in overcoming the threats posed by this pandemic, and to contribute to post-pandemic recovery. DMTC’s role includes coordination and engagement with government agencies, taskforces and other coordination groups engaged in the national response to COVID-19.
The web portal can be accessed via this link below.
Enquiries about use of the portal should be directed to email@example.com
A clinical trial has commenced to test the effectiveness of a low-dose regimen of the anti-malarial drug Chloroquine to prevent coronavirus illness. The trial represents a major Australian contribution to the global effort to tackle COVID-19.
The clinical trial is being funded by Defence and managed by the national Medical Countermeasures Initiative led by DMTC Limited. Experts with experience in clinical trials from DMTC are working alongside personnel at the trial site, the ADF Malaria and Infectious Diseases Institute.
The trial will focus on military healthcare and civilian healthcare workers at the frontline of the national response to COVID-19. Participation in this trial is entirely voluntary, subject to fully informed consent and strict admittance criteria. The trial may involve up to 700 volunteer participants.